findmyKOL

Christopher Sayed, MD

Enriched profile

Professor, Department of Dermatology · University of North Carolina at Chapel Hill School of Medicine

ORCIDNPI
Region🇺🇸 Chapel Hill, NC · Southeast · United StatesSpecialtyDermatologyFocusAcne / Hidradenitis
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2020–2026

Christopher Sayed is Professor, Department of Dermatology at University of North Carolina at Chapel Hill School of Medicine. OpenAlex indexes 171 publications with 2,735 citations (h-index 21); ClinicalTrials.gov lists 3 registered studies with this person as an investigator.

Data verified 25 Aug 2026

Overview

Updated 27 Aug 2026

Christopher Sayed, MD, is Professor, Department of Dermatology at University of North Carolina at Chapel Hill School of Medicine. The public record shows 171 publications with 2,735 citations (h-index 21), centered on Acne / Hidradenitis. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 14 companies, 2 NIH-funded awards (2020–2026).

  • Most recent indexed publication: 2026 · The patient
  • Top research focus: Acne / Hidradenitis
  • 3 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 14 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Acne / Hidradenitis3 trialsHidradenitis Suppurativa3 trialsLymphadenitis3 trialsSurgical Wound1 trialAcne Vulgaris1 trial

Research focus

OpenAlex concept fingerprint
Acne / Hidradenitis

Drugs & molecules

across trials, industry payments and publications
Rinvoqgeneric · UpadacitinibClinical trialsIndustry payments217Publications1Cosentyxgeneric · SecukinumabClinical trialsIndustry payments15Publications1Humirageneric · AdalimumabClinical trialsIndustry payments100Publications

Works with

trial sponsors and companies reporting payments
Abbvie Inc.Clinical trialsIndustry payments361Novartis Pharmaceuticals CorporationClinical trialsIndustry payments18UCB, Inc.Clinical trialsIndustry payments14

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
171publications

Distinct works indexed by OpenAlex, matched via ORCID; 29 in PubMed.

2,735citations

Total citations across indexed works.

21h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
3clinical trials

Investigator role on registered studies.

View trials
14companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
2NIH grants · 2020–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

14 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    39.1%
    TNF inhibitor16.6%
    Humira(Cf) Pen55%Remicade30%Inflectra15%
    Part D<11 patients
    Interleukin-17A Antagonist10.4%
    Cosentyx Unoready Pen89%Taltz Autoinjector11%
    Part D<11 patients
  • Anti-infectives

    32.1%
    Lincosamide Antibacterial5.6%
    Clindamycin Hcl70%Clindamycin Phosphate30%
    Part D<11 patients
    Penem Antibacterial5.2%
    Ertapenem100%
    Part D<11 patients
  • Dermatology

    13.2%
    Corticosteroid13.2%
    Triamcinolone acetonide61%Triamcinolone Acetonide40%
    Part D + Part B31 patients
5 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

2 NIH research awards on record, funded 20202026 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/christoph-sayed-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com

Mentions by others

where others cite or feature them
  • Apple Podcasts

    podcasts.apple.com/us/podcast/derms-on-drugs/id1793832955

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com
  • Other

    hs-foundation.org/christopher-sayed-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hs-foundation.org
  • Other

    webmd.com/podcasts/20251030/when-your-hs-treatments-stop-working-finding-new-paths-to-relief

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →webmd.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • M.D.

    University of North Carolina at Chapel Hill

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu
  • Internal Medicine Internship

    University of North Carolina at Chapel Hill

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu
  • Dermatology Residency

    University of North Carolina at Chapel Hill

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu
  • Board Certified

    Dermatology (American Board of Dermatology)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com

Editorial & leadership roles

journal and society appointments
  • Director

    Hidradenitis Suppurativa Clinic, UNC Chapel Hill

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu
  • Vice President

    Hidradenitis Suppurativa Foundation

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hs-foundation.org
  • Site Principal Investigator

    industry- and NIH-funded HS clinical trials (e.g., BE HEARD I/II bimekizumab studies)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.